Canji Inc.

Schering Corporation

Defiante Farmaceutica, S.a.

Stephen Kenneth Youngster

Tattanahalli L Nagabhushan

Heidrun Engler

David R Filpula

A mutein recombinant adenosine deaminase having any oxidizable cysteine residue replaced by a non-oxidizable amino acid residue is disclosed. Stabilized recombinant adenosine deaminase, polymer conjugates and methods of treatment using the same are also disclosed.

Stable recombinant adenosine deaminase

A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: 

Compositions and methods for therapeutic use

This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.

Compositions and methods for enhancing delivery of therapeutic agents to cells

The present invention is directed to compositions and methods of treating cancer by gene therapy using a therapeutic gene formulated in a buffer comprising a delivery-enhancing agent. The delivery-enhancing agents of the invention can be used to formulate therapeutic or diagnostic agents, such as proteins, nucleic acids, antisense RNA, small molecules, etc., for administration to any tissue or organ having an epithelial membrane. The delivery-enhancing agents include detergents, alcohols, surfactants and other molecules.

Growing community of inventors

Piscataway, NJ, United States of America

Stephen Kenneth Youngster